<DOC>
	<DOCNO>NCT00580073</DOCNO>
	<brief_summary>This study involve use Oxaliplatin , 5-Fluorouracil ( 5-FU ) , Leucovorin Cetuximab , medicine approve Food Drug Administration ( FDA ) commercially available . This treatment regimen possibly combine radiation and/or surgery depend response treatment . Their use exact combination consider experimental . The purpose study find effective combination chemotherapy treatment rectal cancer spread part body . The side effect survival experience subject receive drug also evaluate . This phase II research study .</brief_summary>
	<brief_title>Phase II Trial Neoadjuvant FOLFOX4 Cetuximab Localized Adenocarcinoma Rectum</brief_title>
	<detailed_description>Primary Objective : - Down-staging tumor Secondary Objectives : - Pathologic response rate - Tumor marker response - Incidence sphincter spar surgery - Progression-free survival - Overall Survival</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>All patient must newly diagnose , histologically proven adenocarcinoma rectum . Locally advanced T3 , T4 T N1 , N2 , stag transrectal ultrasound . All patient must abdominal/pelvis CT scan MRI confirm evidence distant metastasis . Patients must ECOG PS â‰¤ 2 Patient sign informed consent Lower Age Limit : 18 year Upper Age Limit : No upper age limit Laboratory parameter : Hgb : &gt; 9.0 g/dl ANC &gt; 1500/ul Platelet &gt; 100,000/ul Creatinine &lt; 2x ULN Bilirubin &lt; 2x ULN ALT &lt; 2x ULN Administration prior systemic anticancer therapy colorectal cancer ( eg , chemotherapy , antibody therapy , immunotherapy , gene therapy , vaccine therapy , cytokine therapy , angiogenesis inhibitor ) . Previous intraarterial cytotoxic chemotherapy give treatment colorectal cancer . Previous pelvic radiotherapy . Known allergy intolerance oxaliplatin , 5FU , cetuximab leucovorin . Pregnant breastfeed woman : female patient must agree use effective contraception , must surgically sterile , must postmenopausal . Male patient must agree use effective contraception surgically sterile . The definition effective contraception base judgment principal investigator designate associate . All atrisk female patient must negative serum pregnancy test within 7 day prior registration . Active inflammatory bowel disease , significant bowel obstruction , chronic diarrhea ( grade 2 ) . Myocardial infarction stroke within previous 6 month , ongoing unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac dysrhythmia . Known human immunodeficiency virus ( HIV ) positivity acquiredimmunodeficiencysyndrome ( AIDS ) relate illness . No previous concurrent malignancy allow except adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , cancer patient diseasefree 3 year . Known CNS metastasis Preexisting neuropathy &gt; Grade 2 Prior therapy specifically directly target EGFR pathway Prior severe infusion reaction monoclonal antibody Significant history uncontrolled cardiac disease ; i.e. , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure cardiomyopathy decrease ejection fraction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>